

## Methacycline hydrochloride

## Chemical Properties


CAS No. : 3963-95-9

Formula: C<sub>22</sub>H<sub>23</sub>ClN<sub>2</sub>O<sub>8</sub>

Molecular Weight: 478.88

Storage: Keep away from direct sunlight, Store under nitrogen  
Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



## Biological Description

|               |  |
|---------------|--|
| Description   | Methacycline hydrochloride (Randomycin) is a broad-spectrum semisynthetic antibiotic related to TETRACYCLINE but excreted more slowly and maintaining effective blood levels for a more extended period.   |
| Targets(IC50) | ribosome, Antibacterial, Antibiotic  |
| In vitro      | Methacycline, within pulmonary alveolar macrophages, does not alter the response gene of TGF-β1 nor attenuates the aggregation of inflammatory cells. Following tracheal aspiration of bleomycin, intraperitoneal injection of Methacycline at 100 mg/kg, starting on day 10, enhances survival rates by day 17. Methacycline mitigates bleomycin-induced classical EMT (Epithelial-Mesenchymal Transition) markers, including SNAIL1, TWIST1, type I collagen, fibronectin, and their mRNA expressions. |
| In vivo       | Methacycline inhibits the TGF-β1-induced non-Smad signaling pathways, including the activation of c-Jun N-terminal kinase (JNK), p38, and Akt, without suppressing Smad or β-catenin transcriptional activities. It does not affect the baseline activities of JNK, p38, or Akt, nor the TGF-β1 response of lung fibroblasts. Additionally, methacycline inhibits the TGF-β1-induced expression of α-smooth muscle actin (α-SMA), SNAIL1, and type I collagen in primary alveolar epithelial cells.      |

## Solubility Information

|                     |  |
|---------------------|--|
| Solubility          | DMSO: 27.5 mg/mL (57.43 mM), Sonication is recommended.<br>(< 1 mg/ml refers to the product slightly soluble or insoluble)   |
| In vivo Formulation | 10% DMSO+90% Saline: 2 mg/mL (4.18 mM), Sonication is recommended.<br><i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i> |

### Preparing Stock Solutions

---

|       | <b>1mg</b> | <b>5mg</b> | <b>10mg</b> |
|-------|------------|------------|-------------|
| 1 mM  | 2.0882 mL  | 10.441 mL  | 20.8821 mL  |
| 5 mM  | 0.4176 mL  | 2.0882 mL  | 4.1764 mL   |
| 10 mM | 0.2088 mL  | 1.0441 mL  | 2.0882 mL   |
| 50 mM | 0.0418 mL  | 0.2088 mL  | 0.4176 mL   |

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

#### Reference

Xi Y, et al. Am J Respir Cell Mol Biol, 2014, 50(1), 51-60.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E\_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481